Overview
What is Montana Cancer Consortium?
The Montana Cancer Consortium is an independent, nonprofit organization situated in Billings, Montana. Their primary mission is to advance cancer research and treatment in the region, extending their reach to neighboring states Idaho and Wyoming. They participate in National Cancer Institute (NCI) sponsored clinical trials, offering experimental drugs to selected cancer patients and meticulously tracking the outcomes of these treatments. In the year 2022, they were involved in around 120 clinical trials and registered over 300 patients. The consortium comprises approximately 51 physician members spread across 10 affiliate sites in Montana, Northern Wyoming, and Idaho, collaborating to bring state-of-the-art cancer treatment to the community.
Official website here: www.mtcancer.org
Is Montana Cancer Consortium legitimate?
Montana Cancer Consortium is a legitimate nonprofit organization registered as a 501(c)(3) entity. Montana Cancer Consortium submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $116,000
Professional Fundraising Fees: $0
Other Salaries and Wages: $200,750
For more financial information, click here
Official website here: www.mtcancer.org
What is the mission statement of Montana Cancer Consortium?
The Montana Cancer Consortium (MCC) serves as an independent nonprofit organization with a mission to advance cancer treatment in the regions of Montana, Idaho, and Wyoming. This is achieved through participation in National Cancer Institute (NCI) sponsored clinical research, aiming to make state-of-the-art cancer treatments accessible to the community. The MCC contributes to clinical studies involving cancer patients, offering experimental drugs to selected candidates and meticulously documenting the results of these treatments. In the recent year ending May 31, 2022, the MCC took part in approximately 120 clinical trials and registered around 330 patients for these trials. The membership of the MCC includes around 51 physician members located across 10 affiliate sites in the mentioned regions.
Official website here: www.mtcancer.org
Who is the CEO of Montana Cancer Consortium?
John Schallenkamp Md is the President of Montana Cancer Consortium.
Official website here: www.mtcancer.org
What is the revenue of Montana Cancer Consortium?
Who are the executives of Montana Cancer Consortium and what are their salaries?
The average compensation at Montana Cancer Consortium during 2022 was $45,250. There are 7 employees and 8 volunteers at Montana Cancer Consortium.
Here are 9 key members and their salaries:
- Amanda Disndale (Secretary/Treasurer) [Trustee/Director]
- John Schallenkamp Md (President) [Trustee/Director]
- Jeffrey Allen Md (Vice-President) [Trustee/Director]
- Justin Bottsford-Miller Md (Vice-President) [Trustee/Director]
- Benjamin Marchello Md (Director)
- Michelle Proper Md (Director)
- Christopher Goulet Md (Director)
- James Hueftle Md (Director)
- Justin Thomas Md (Director)
Official website here: www.mtcancer.org
Where can I find the form 990 for Montana Cancer Consortium?
The Montana Cancer Consortium’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.mtcancer.org
Learn more at the official website: www.mtcancer.org
Mission Statement of Montana Cancer Consortium
The Montana Cancer Consortium (MCC) is a dedicated, independent nonprofit organization with a mission to advance cancer research in the regions of Montana, Idaho, and Wyoming. By partnering with the National Cancer Institute (NCI), MCC aims to make cutting-edge cancer treatment available to these areas, enabling patients to access experimental medicines and participate in clinical studies. In the year ending May 31, 2022, the Montana Cancer Consortium participated in approximately 120 clinical trials, registering over 330 patients to these trials. The organization's membership is comprised of approximately 51 physician members, strategically located across 10 affiliate sites in Montana, Northern Wyoming, and Idaho.
Impact
This information is meant to be a general summary of Montana Cancer Consortium. Please take the time to review official sources before making any decisions based upon the content provided here.
Saturday, July 20, 2024
The Montana Cancer Consortium has a significant impact on cancer research and treatment in the region. Through its participation in clinical studies, provision of experimental drugs to selected candidates, and meticulous data collection on treatment outcomes, the consortium plays a crucial role in advancing cancer care. In the year ending May 31, 2022, the Montana Cancer Consortium engaged in approximately 120 clinical trials and registered 330 patients for these trials. With a network of 51 physician members spread across 10 affiliate sites in Montana, Northern Wyoming, and Idaho, the consortium is dedicated to delivering state-of-the-art cancer treatment to the community.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Organization Details
Founding Year
1995
Phone
(406) 969-6060
Principal Officer
John Schallenkamp Md
Main Address
2132 Broadwater Avenue A1, Billings, MT, 59102
Website
www.mtcancer.org
NTEE Category
Code: G30 - Disease
If you are a representative of Montana Cancer Consortium and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.